ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...

In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across ...

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data ...

Mutation of HELLS (Helicase, Lymphoid-Specific)/Lsh in human DNA causes a severe immunodeficiency syndrome, but the nature of the defect remains unknown. We assessed here the role of Lsh in ...

Creative Biolabs provides an end-to-end platform for researchers developing tumor-infiltrating lymphocyte (TIL) therapies, offering specialized services from cell isolation to characterization that ...

Scientists provide a comprehensive overview of the evolution and potential of TIL therapy. They describe its development and highlight its transformative potential. The recent U.S. Food and Drug ...

Heart attacks and strokes, leading causes of deaths globally, arise from thrombotic occlusion of ruptured vulnerable atherosclerotic plaques characterized by abundant apoptosis, large necrotic cores ...

KSQ Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for solid tumors, announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited ...

From the Vascular Biology and Atherosclerosis Laboratory, Baker IDI Heart and Diabetes Institute, Victoria, Australia (T.K., A.W., C.T., P.K., H.H., P.L., A.B ...

LEXINGTON, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, Inc. ("KSQ"), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics ® discovery platform, and CTMC, ...